$1.19
-0.045-3.64%
At close: Nov 11, 4:00 PM EST
$1.21
-0.025-2.02%
Pre-Market: 4:00 AM EST
Autolus Therapeutics PLC
AUTLNASDAQ
Autolus Therapeutics (AUTL) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
| Fiscal Quarter | Date Reported | Actual EPS | Estimated EPS | Surprise % |
|---|---|---|---|---|
| Q3 | Nov 10, 2026 | $-0.21 | $-0.18 | -16.7 % |
| Q2 | Aug 11, 2026 | $-0.15 | $-0.19 | 21.1 % |
| Q1 | May 14, 2026 | $-0.27 | $-0.27 | 0.00 % |
| Q4 | Mar 27, 2026 | $-0.34 | $-0.38 | 10.5 % |
Quarterly Revenue (Billions)
| Fiscal Quarter | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
|---|---|---|---|---|
| Q3 | Nov 10, 2026 | $41.24M | $39.77M | 3.69 % |
| Q2 | Aug 11, 2026 | $45.69M | $41.14M | 11.1 % |
| Q1 | May 14, 2026 | $26.22M | $26.16M | 0.22 % |
| Q4 | Mar 27, 2026 | $24.29M | $23.24M | 4.51 % |
Autolus Therapeutics (AUTL) last issued guidance on November 10, 2026 for fiscal year 2026. The company guided revenue in the range of for the period.
Compared to prior guidance, Autolus Therapeutics maintained its revenue forecast from a prior range of $140M - $150M.
Autolus Therapeutics has issued 3 guidance updates between May 14, 2026 and August 11, 2026. During this period, the company raised its outlook 1 time, reflecting management's growing confidence in business performance.
| Metric | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-0.18 | $-0.19 | $-0.27 | $-0.38 |
| Actual | $-0.21 | $-0.15 | $-0.27 | $-0.34 |
| Surprise | -16.7% | +21.1% | 0.00% | +10.5% |
| Revenue | ||||
| Estimate | $39.8M | $41.1M | $26.2M | $23.2M |
| Actual | $41.2M | $45.7M | $26.2M | $24.3M |
| Surprise | +3.69% | +11.1% | +0.22% | +4.51% |
| Metric | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|
| Earnings Per Share (Non-GAAP) | |||
| Consensus | $-0.18 | $-0.17 | $-0.19 |
| Revenue | |||
| Consensus | $38.5M | $43.4M | — |
